The FDA urged clinical trial sponsors to report results after an internal review found that outcomes were missing for about 30% of registered studies. The agency sent reminders to roughly 2,200 companies and research organizations, spanning drugmakers, medical device manufacturers, and investigators, emphasizing that trial results submission is required even when programs do not advance. The action comes as regulators try to reduce information gaps that can slow evidence generation and distort the overall clinical record. The FDA’s push is likely to increase compliance scrutiny across sponsors’ study management systems and reporting workflows. For biotech operators, the reminder underscores the regulatory and reputational risk of incomplete results disclosure and may accelerate adoption of more robust trial reporting processes.